Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients

Rodney G. Bowden, Jean Gutierrez, Ronald L. Wilson, Mindy Gentile

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Our purpose was to determine if over-the-counter fish oil improves the cardiovascular-disease risk profile of endstage renal disease patients. Design: This study used a double-blind, permuted-block, randomized, placebo-controlled design. The experimental intervention consisted of fish-oil concentrate supplementation, whereas corn-oil capsules were used as a control. Compliance follow-ups were performed 3 times per week. Setting: Patients of Central Texas Nephrology Associates clinics were eligible for this study. Patients: Exclusion criteria comprised a life-expectancy of less than 6 months, pregnancy, a history of hemodialysis or medication noncompliance, or age below 18 years. The final sample size was 87 patients. The attrition rate was 9%. Intervention: Participants in the experimental group consumed six 1-g soft-gel capsules of fish-oil concentrate each day for 6 months. The control group consumed corn-oil capsules, following the same protocol. Venous blood samples were acquired before and after the intervention. Main Outcome Measure: We assessed a number of serum lipid indicators. Results: There were significant supplement/time interactions in low-density lipoprotein cholesterol (LDL) levels (P = .0001) and LDL particle number (P = .0001). Repeated-measures analysis of variance revealed significant time trends in high-density lipoprotein cholesterol (P = .012) and LDL (P = .001). High-density lipoprotein cholesterol levels significantly decreased in the control group, and increased in the fish-oil group, at 6 months, and LDL levels increased significantly in both groups. Conclusions: The analysis indicates mixed results with respect to cardiovascular disease risk. Further research is needed to assess the benefits of an over-the-counter fish-oil supplement in the renal population.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalJournal of Renal Nutrition
Volume19
Issue number4
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Fish Oils
Omega-3 Fatty Acids
LDL Cholesterol
Kidney
Lipids
Capsules
Corn Oil
HDL Cholesterol
Cardiovascular Diseases
Reproductive History
Control Groups
Nephrology
Medication Adherence
Life Expectancy
Sample Size
Compliance
Renal Dialysis
Analysis of Variance
Gels
Placebos

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Nephrology

Cite this

Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients. / Bowden, Rodney G.; Gutierrez, Jean; Wilson, Ronald L.; Gentile, Mindy.

In: Journal of Renal Nutrition, Vol. 19, No. 4, 01.07.2009, p. 259-266.

Research output: Contribution to journalArticle

Bowden, Rodney G. ; Gutierrez, Jean ; Wilson, Ronald L. ; Gentile, Mindy. / Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients. In: Journal of Renal Nutrition. 2009 ; Vol. 19, No. 4. pp. 259-266.
@article{aab5cf7d4e014b36a79cdb87d9005cba,
title = "Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients",
abstract = "Objective: Our purpose was to determine if over-the-counter fish oil improves the cardiovascular-disease risk profile of endstage renal disease patients. Design: This study used a double-blind, permuted-block, randomized, placebo-controlled design. The experimental intervention consisted of fish-oil concentrate supplementation, whereas corn-oil capsules were used as a control. Compliance follow-ups were performed 3 times per week. Setting: Patients of Central Texas Nephrology Associates clinics were eligible for this study. Patients: Exclusion criteria comprised a life-expectancy of less than 6 months, pregnancy, a history of hemodialysis or medication noncompliance, or age below 18 years. The final sample size was 87 patients. The attrition rate was 9{\%}. Intervention: Participants in the experimental group consumed six 1-g soft-gel capsules of fish-oil concentrate each day for 6 months. The control group consumed corn-oil capsules, following the same protocol. Venous blood samples were acquired before and after the intervention. Main Outcome Measure: We assessed a number of serum lipid indicators. Results: There were significant supplement/time interactions in low-density lipoprotein cholesterol (LDL) levels (P = .0001) and LDL particle number (P = .0001). Repeated-measures analysis of variance revealed significant time trends in high-density lipoprotein cholesterol (P = .012) and LDL (P = .001). High-density lipoprotein cholesterol levels significantly decreased in the control group, and increased in the fish-oil group, at 6 months, and LDL levels increased significantly in both groups. Conclusions: The analysis indicates mixed results with respect to cardiovascular disease risk. Further research is needed to assess the benefits of an over-the-counter fish-oil supplement in the renal population.",
author = "Bowden, {Rodney G.} and Jean Gutierrez and Wilson, {Ronald L.} and Mindy Gentile",
year = "2009",
month = "7",
day = "1",
doi = "10.1053/j.jrn.2009.01.030",
language = "English (US)",
volume = "19",
pages = "259--266",
journal = "Journal of Renal Nutrition",
issn = "1051-2276",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients

AU - Bowden, Rodney G.

AU - Gutierrez, Jean

AU - Wilson, Ronald L.

AU - Gentile, Mindy

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Objective: Our purpose was to determine if over-the-counter fish oil improves the cardiovascular-disease risk profile of endstage renal disease patients. Design: This study used a double-blind, permuted-block, randomized, placebo-controlled design. The experimental intervention consisted of fish-oil concentrate supplementation, whereas corn-oil capsules were used as a control. Compliance follow-ups were performed 3 times per week. Setting: Patients of Central Texas Nephrology Associates clinics were eligible for this study. Patients: Exclusion criteria comprised a life-expectancy of less than 6 months, pregnancy, a history of hemodialysis or medication noncompliance, or age below 18 years. The final sample size was 87 patients. The attrition rate was 9%. Intervention: Participants in the experimental group consumed six 1-g soft-gel capsules of fish-oil concentrate each day for 6 months. The control group consumed corn-oil capsules, following the same protocol. Venous blood samples were acquired before and after the intervention. Main Outcome Measure: We assessed a number of serum lipid indicators. Results: There were significant supplement/time interactions in low-density lipoprotein cholesterol (LDL) levels (P = .0001) and LDL particle number (P = .0001). Repeated-measures analysis of variance revealed significant time trends in high-density lipoprotein cholesterol (P = .012) and LDL (P = .001). High-density lipoprotein cholesterol levels significantly decreased in the control group, and increased in the fish-oil group, at 6 months, and LDL levels increased significantly in both groups. Conclusions: The analysis indicates mixed results with respect to cardiovascular disease risk. Further research is needed to assess the benefits of an over-the-counter fish-oil supplement in the renal population.

AB - Objective: Our purpose was to determine if over-the-counter fish oil improves the cardiovascular-disease risk profile of endstage renal disease patients. Design: This study used a double-blind, permuted-block, randomized, placebo-controlled design. The experimental intervention consisted of fish-oil concentrate supplementation, whereas corn-oil capsules were used as a control. Compliance follow-ups were performed 3 times per week. Setting: Patients of Central Texas Nephrology Associates clinics were eligible for this study. Patients: Exclusion criteria comprised a life-expectancy of less than 6 months, pregnancy, a history of hemodialysis or medication noncompliance, or age below 18 years. The final sample size was 87 patients. The attrition rate was 9%. Intervention: Participants in the experimental group consumed six 1-g soft-gel capsules of fish-oil concentrate each day for 6 months. The control group consumed corn-oil capsules, following the same protocol. Venous blood samples were acquired before and after the intervention. Main Outcome Measure: We assessed a number of serum lipid indicators. Results: There were significant supplement/time interactions in low-density lipoprotein cholesterol (LDL) levels (P = .0001) and LDL particle number (P = .0001). Repeated-measures analysis of variance revealed significant time trends in high-density lipoprotein cholesterol (P = .012) and LDL (P = .001). High-density lipoprotein cholesterol levels significantly decreased in the control group, and increased in the fish-oil group, at 6 months, and LDL levels increased significantly in both groups. Conclusions: The analysis indicates mixed results with respect to cardiovascular disease risk. Further research is needed to assess the benefits of an over-the-counter fish-oil supplement in the renal population.

UR - http://www.scopus.com/inward/record.url?scp=67149141764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149141764&partnerID=8YFLogxK

U2 - 10.1053/j.jrn.2009.01.030

DO - 10.1053/j.jrn.2009.01.030

M3 - Article

VL - 19

SP - 259

EP - 266

JO - Journal of Renal Nutrition

JF - Journal of Renal Nutrition

SN - 1051-2276

IS - 4

ER -